durvalumab,oleclumab,monalizumab
astrazeneca,innate
['nsclc', 'monali', 'pacific,(-pacifica),(-pacific 6),(-pacific6),(-pacific-6),(-pacific-a),(-pacific a)', 'durva', 'oleclumab', 'sclc']
#asco23 #posters
phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage iii nsclc (pacific-9) bd#231b 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | AD @PC31 | Incoming Chair @ASCO #CCC | Tweets my own | COI: https://t.co/ghKU8KhBvl